After ruling out myelodysplastic and other myeloproliferative diseases the patient was finally diagnosed as aCML according to the WHO criteria with mutations in the TET2 gene, the NRAS gene and in the KRAS gene. This evidence concerns the gene TET2 and atypical chronic myeloid leukemia, BCR-ABL1 negative.